Table 1 Baseline characteristics of study patients with CRMO.
Total number of patients | 9 |
|---|---|
Sex (F:M) | 5:4 |
Age at pamidronate treatment (y)* | 12.9 (4.5–16.3) |
Duration of symptoms before IVP (m)* | 18 (6–36) |
HLA-B27 positive (n) | 3/9 |
VAS for pain pre-IVP (scale 0–10) | 10/10 for all patients |
Functional limitation pre-pamidronate | Â |
   Prolonged school/daycare absences (n) | 9/9 |
   Hospitalized for pain management (n) | 4/9 |
   Limited use of upper limb (n) | 3/9 |
   Difficulty weight bearing (n); requiring crutches (n) | 5/9; 2/9 |
   Bedridden from spinal/leg pain (n) | 2/9 |
Extra-osseus manifestations at baseline | Â |
   Psoriasis/palmoplantar pustulosis/acne | 0/9 |
   Synovitis/inflammatory bowel disease | 0/9 |
Number of patients with elevated ESR at baseline | 6/9 |
   ESR value (range) at baseline (normal < 10 mm/Hg)* | 23.7 (3–52 mm/Hg) |
Bone involvement pre-IVP as documented by MRI | Â |
   Number of affected sites* | 3.5 (2–9) |
   Clavicle (n) | 2/9 |
   Sacroiliac joint region (n) | 2/9 |
   Distal fibula (n) | 2/9 |
   Distal femur (n) | 4/9 |
   Vertebrae (n; range for number of involved vertebrae) | 2/9 (3–9) |
   Distal tibia (n) | 2/9 |
   Proximal humerus (n) | 1/9 |
   Distal radius (n) | 1/9 |
Clinically evident adjacent soft tissue swelling pre-pamidronate | Â |
   Number of patients | 5/9 |
Bone histopathology | Â |
   Number of patients with bone biopsies** (n) | 9/9 |
   Active inflammation only (n) | 5/9 |
   Chronic inflammation only (n) | 1/9 |
   Active and chronic inflammation (n) | 3/9 |
   Increased bone resorption and osteoclasts (n) | 1/9 |
   Necrotic bone (n) | 2/9 |
   Reactive new bone (n) | 1/9 |
Previous treatment pre-IVP | Â |
   Nonsteroidal anti-inflammatory drugs (n)*** | 9/9 |
   Sulfasalazine (50 mg/kg/day) (n) | 1/9 |
   Prednisone (oral, 10 mg/day) (n) | 1/9 |
   Codeine (n) | 9/9 |
   Fentanyl (n) | 3/9 |
   Morphine (n) | 1/9 |
   Ketorolac (n) | 1/9 |
   Amitriptyline (n) | 1/9 |
   Surgical courettage (n) | 2/9 |